Sunday, 4 October 2026European Markets

CRCAM NORM.SEINE, CRCAM LOIRE HTE L., Another 2 Companies Have A High Estimated Dividend Yield

Loading stream...

(vianews) - crcam norm.seine (ccn.pa), crcam loire hte l. (crlo.pa), crcam loire hte l. (crlo.pa) have the highest dividend yield stocks on this list.

financial asset forward dividend yield updated (est)
crcam norm.seine (ccn.pa) 5.26% 2024-01-03 09:01:44
crcam loire hte l. (crlo.pa) 5.2% 2024-01-03 09:01:39
crcam loire hte l. (crlo.pa) 5.2% 2024-01-03 09:01:39
eurofins scient. (erf.pa) 2.16% 2024-01-03 09:02:59

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam norm.seine (ccn.pa)

5.26% foward dividend yield

crcam norm.seine's last close was €77.48, 9.89% under its 52-week high of €85.98. intraday change was -1.28%.

caisse régionale de crédit agricole mutuel de normandie-seine société cooperativ offers various banking products and services to individuals, professionals, farmers, associations, and companies in france. it provides savings accounts; credit products; property, personal, life, and pension insurance products; factoring; brokerage; investment banking; asset management; real estate promotion services; specialized funding products; and various loans. the company was incorporated in 2000 and is headquartered in bois guillaume, france. caisse régionale de crédit agricole mutuel de normandie-seine société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam norm.seine has a trailing twelve months eps of €13.51.

pe ratio

crcam norm.seine has a trailing twelve months price to earnings ratio of 5.7. meaning, the purchaser of the share is investing €5.7 for every euro of annual earnings.

volume

today's last reported volume for crcam norm.seine is 63 which is 70.14% below its average volume of 211.

volatility

crcam norm.seine's last week, last month's, and last quarter's current intraday variation average was a negative 0.67%, a positive 0.08%, and a positive 0.72%.

crcam norm.seine's highest amplitude of average volatility was 0.67% (last week), 0.76% (last month), and 0.72% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 0.8%, now sitting on 346.98m for the twelve trailing months.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 15, 2023, the estimated forward annual dividend rate is 4.1 and the estimated forward annual dividend yield is 5.26%.

more news about crcam norm.seine.

2. crcam loire hte l. (crlo.pa)

5.2% foward dividend yield

crcam loire hte l.'s last close was €56.50, 15.24% below its 52-week high of €66.66. intraday change was -2.17%.

caisse régionale de crédit agricole mutuel loire haute-loire société coopérative provides various banking products and services to individuals, professionals, farmers, business, public community and social housing, and associations in france. it offers accounts and cards; real estate loans and consumer credit; operating cycle, and company equipment and real estate financing; trade and export financing; savings products, such as life insurance, real estate investments, stock exchanges and financial investment, and retirement saving solutions; car and two-wheeler, home, personal, leisure and daily life, borrower, professional premises, professional vehicle, health, employee, activity, agricultural buildings, agricultural equipment and activity, and other insurance products; collection and payment services; cash management, business creation financing, medium-term credit, and leasing products; and treasury services. the company is based in saint-étienne, france. caisse régionale de crédit agricole mutuel loire haute-loire société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam loire hte l. has a trailing twelve months eps of €9.22.

pe ratio

crcam loire hte l. has a trailing twelve months price to earnings ratio of 6.03. meaning, the purchaser of the share is investing €6.03 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4%.

volume

today's last reported volume for crcam loire hte l. is 58 which is 63.52% below its average volume of 159.

more news about crcam loire hte l..

3. crcam loire hte l. (crlo.pa)

5.2% foward dividend yield

crcam loire hte l.'s last close was €56.50, 15.24% under its 52-week high of €66.66. intraday change was -2.17%.

caisse régionale de crédit agricole mutuel loire haute-loire société coopérative provides various banking products and services to individuals, professionals, farmers, business, public community and social housing, and associations in france. it offers accounts and cards; real estate loans and consumer credit; operating cycle, and company equipment and real estate financing; trade and export financing; savings products, such as life insurance, real estate investments, stock exchanges and financial investment, and retirement saving solutions; car and two-wheeler, home, personal, leisure and daily life, borrower, professional premises, professional vehicle, health, employee, activity, agricultural buildings, agricultural equipment and activity, and other insurance products; collection and payment services; cash management, business creation financing, medium-term credit, and leasing products; and treasury services. the company is based in saint-étienne, france. caisse régionale de crédit agricole mutuel loire haute-loire société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam loire hte l. has a trailing twelve months eps of €9.22.

pe ratio

crcam loire hte l. has a trailing twelve months price to earnings ratio of 6.03. meaning, the purchaser of the share is investing €6.03 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4%.

volume

today's last reported volume for crcam loire hte l. is 58 which is 63.52% below its average volume of 159.

revenue growth

year-on-year quarterly revenue growth grew by 4.6%, now sitting on 413.81m for the twelve trailing months.

moving average

crcam loire hte l.'s worth is under its 50-day moving average of €57.49 and below its 200-day moving average of €59.27.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 31, 2023, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 5.2%.

more news about crcam loire hte l..

4. eurofins scient. (erf.pa)

2.16% foward dividend yield

eurofins scient.'s last close was €57.86, 20.35% below its 52-week high of €72.64. intraday change was -3.15%.

eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and technologies services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, eurofins scient. has a trailing twelve months eps of €2.28.

pe ratio

eurofins scient. has a trailing twelve months price to earnings ratio of 25.36. meaning, the purchaser of the share is investing €25.36 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.12%.

moving average

eurofins scient.'s value is higher than its 50-day moving average of €52.99 and under its 200-day moving average of €59.57.

more news about eurofins scient..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com